EchinocandinsB市場按產品類型、給藥途徑、劑型、劑量方案、包裝、通路、應用和最終用戶分類－2026-2032年全球預測

2025 年EchinocandinsB 市值為 2.6782 億美元，預計到 2026 年將成長至 3.0595 億美元，年複合成長率為 12.54%，到 2032 年將達到 6.1234 億美元。

關鍵市場統計數據
基準年 2025	2.6782億美元
預計年份：2026年	3.0595億美元
預測年份 2032	6.1234億美元
複合年成長率 (%)	12.54%

棘Echinocandins療法概述：重點關注臨床重要性、後勤挑戰以及治療連續性的策略要務

Echinocandins已成為治療嚴重侵襲性真菌感染疾病的基石，它們憑藉良好的治療指數和定向活性，與現有抗真菌藥物物形成互補。這些藥物在現代侵襲性念珠菌症臨床通訊協定中至關重要，並且在某些食道念珠菌症和侵襲性麴菌症病例中，當治療複雜且需要可靠的靜脈治療時，它們也是重要的治療選擇。過去十年，臨床實務強調合理用藥、快速診斷，以最佳化治療效果並降低抗藥性壓力。

製劑創新、競標趨勢和不斷發展的治療途徑正在全面重塑Echinocandins療法的生產、採購和使用。

Echinocandins藥物領域正經歷著變革性的轉變，這主要得益於製劑科學的進步、採購機制的轉變以及臨床指南的不斷完善，這些因素共同改變了此類治療方法的生產、採購和給藥方式。近期製劑的創新，特別是複溶凍乾製劑和預填充式注射器等產品，縮短了配製時間，最大限度地減少了給藥錯誤，並促使醫院和專科診所重新思考住院和門診病人輸液給藥方案。因此，藥局部門越來越重視那些能夠提高護理效率和減少病房佔用時間的產品。

對 2025 年貿易政策調整如何加劇Echinocandins藥物供應鏈的供應鏈風險、採購做法和進入優先事項進行綜合評估。

美國2025年實施的關稅政策為棘Echinocandins供應鏈和臨床供應途徑帶來了巨大的成本和物流壓力。上游方面，生產商面臨活性藥物成分和特殊材料的採購成本上漲，這給生產計畫帶來了壓力，並促使多家契約製造生產商重新評估其地理位置和供應商多元化策略。這些變化對前置作業時間和庫存緩衝產生了直接影響，導致醫院和門診中心的採購團隊更加重視多源資格認證和安全庫存通訊協定。

多維細分分析揭示了產品特性、臨床應用和分銷方式如何決定採購、管理和臨床結果的機制。

詳細的市場細分評估揭示了產品類型、適應症、終端用戶環境、分銷管道、給藥途徑、製劑形式、給藥方案和包裝形式等方面的顯著差異，這些差異共同影響著採購和臨床決策。在產品類型方面，阿尼芬淨、卡芬淨和Micafungin各自展現出不同的臨床定位和操作特性，並且均有品牌藥和非專利兩種形式，這會影響合約策略和處方集目錄的收錄。臨床醫生會考慮這些治療差異以及食道念珠菌症、侵襲性麴菌症和侵襲性念珠菌症等適應症。疾病嚴重程度和患者合併症情況指南具體的藥物選擇和給藥方案。

從區域觀點探討採購系統、製造地和臨床實踐模式如何獨特地影響Echinocandins的可近性和治療的連續性。

區域趨勢正顯著影響Echinocandins的供應、使用模式和運作方式，導致美洲、歐洲、中東和非洲以及亞太地區的優先事項各不相同。在美洲，以醫院為中心的醫療模式和集中採購框架推動了大規模競標，並促使醫療機構更加關注供應可靠性；同時，監管協調和管理計劃也影響處方模式和藥品目錄的發展。這些特點使得醫療機構更加重視與供應商建立牢固的關係，並緊急時應對計畫以應對供應中斷。

透過供應保障、配方差異化和附加價值服務模式，為製造商、契約製造製造商和經銷商提供競爭優勢洞察。

製造商、契約製造製造商和經銷商之間的競爭在塑造供應可靠性、產品差異化和商業策略方面發揮核心作用。藥物研發公司和成熟供應商正投資於配方改進、供應鏈透明度和競標應對力，以維持與醫院集團和採購聯盟的長期合作關係。同時，學名藥參與企業和契約製造組織正在拓展認證和生產能力，以便參與多個競標框架，從而增加大規模買家的採購選擇。

為加強Echinocandins療法的採購彈性、臨床協作和供應鏈韌性，提出實際有效的建議

為了因應不斷變化的Echinocandins市場環境，產業領導者應採取多管齊下的策略，全面保障臨床治療的連續性、採購的彈性和供應鏈的韌性。首先，應優先考慮供應商多元化和雙重採購安排，以降低單一故障點的風險，並協商合約保障條款，包括採購量柔軟性和違約處罰。其次，應投資於製劑和工作流程的完整性，優先選擇能夠縮短配製時間的產品（例如，可複溶的凍乾製劑和預填充式注射器），從而減輕藥房的負擔並最大限度地降低無菌風險。

一項基於實證的混合調查方法，結合了臨床醫生訪談、供應鏈圖譜分析和情境檢驗，得出了可操作且可複製的研究結果。

本分析所依據的研究結合了定性研究、系統的二手文獻綜述以及基於情景的供應鏈映射，以確保結論的穩健性和實用性。主要研究方法包括對感染疾病專家、醫院藥劑師、採購負責人和專科診所主任進行結構化訪談，以收集有關臨床偏好、競標趨勢和管理挑戰的第一手觀點。此外，與物流負責人和契約製造製造商的討論也為生產限制和分銷方面的考慮提供了參考。

簡明綜合分析強調，需要將臨床優先事項與採購的韌性和運作嚴謹性相結合，以維持Echinocandins療法的可及性。

綜合分析結果支持一個核心結論：要提供持續、高品質的Echinocandins療法，需要將臨床優先事項與穩健的採購系統和靈活的供應鏈結合。雖然臨床療效仍然是不可動搖的基礎，但製劑選擇、分銷策略和採購機制對療效能否轉化為及時的患者照護有顯著影響。諸如配藥工作量、低溫運輸要求和競標主導的採購行為等現實挑戰，需要將臨床醫生、藥房營運和商業夥伴連接起來的綜合解決方案。

目錄

第1章：序言

第2章調查方法

• 研究設計
• 研究框架
• 市場規模預測
• 數據三角測量
• 調查結果
• 調查前提
• 調查限制

第3章執行摘要

• 首席主管觀點
• 市場規模和成長趨勢
• 2025年市佔率分析
• FPNV定位矩陣，2025
• 新的商機
• 下一代經營模式
• 產業藍圖

第4章 市場概覽

• 產業生態系與價值鏈分析
• 波特五力分析
• PESTEL 分析
• 市場展望
• 上市策略

第5章 市場洞察

• 消費者洞察與終端用戶觀點
• 消費者體驗基準
• 機會地圖
• 分銷通路分析
• 價格趨勢分析
• 監理合規和標準框架
• ESG與永續性分析
• 中斷和風險情景
• 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章EchinocandinsB市場依產品類型分類

• 原料藥（API）
  • 粗製棘EchinocandinsB
  • 純化棘EchinocandinsB
• 衍生物的中間體
  • 卡福芬淨中間體
  • Micafungin中間體
  • 阿尼芬淨中間體
• 最終配方
  • 注射劑
  • 口服製劑
• 標準材料
• 客製合成

第9章EchinocandinsB市場，依給藥途徑分類

• 靜脈注射
  • 持續輸注
  • 間歇輸注

第10章 棘EchinocandinsB市場（以劑型分類）

• 凍乾粉
  • 手動重新配置
  • 準備重新配置
• 預填充式注射器

第11章 棘EchinocandinsB市場依劑量方案

• 每天一次
  • 高劑量
  • 標準劑量
• 一天兩次
  • 高劑量
  • 標準劑量

第12章EchinocandinsB市場依包裝分類

• 多劑量包裝
• 單劑量包裝

第13章EchinocandinsB市場依通路分類

• 醫院藥房
  • 直接競標
  • 第三方競標
• 網路藥房
• 零售藥房

第14章 棘EchinocandinsB市場：依應用

• 治療研發
  • 抗真菌藥物研發
  • 聯合治療研發
• 商業生產
  • 原料藥生產
  • 製藥生產
• 研究與開發
  • 作用機轉研究
  • 電阻譜分析
  • 藥物動力學研究
  • 毒性測試
• 品管/分析
  • 參考標準物質
  • 檢測標準化
  • 穩定性測試
• 診斷用途
  • 黴菌藥物敏感性試驗
  • 生物標記檢測方法開發

第15章EchinocandinsB市場：依最終用戶分類

• 製藥和生物技術公司
  • 品牌製藥商
  • 學名藥生產商
  • 契約製造組織
• CRO（受託研究機構）
• 學術和研究機構
• 診斷實驗室
• 政府和非營利研究機構

第16章EchinocandinsB市場區域分類

• 美洲
  • 北美洲
  • 拉丁美洲
• 歐洲、中東和非洲
  • 歐洲
  • 中東
  • 非洲
• 亞太地區

第17章EchinocandinsB市場：依組別分類

• ASEAN
• GCC
• EU
• BRICS
• G7
• NATO

第18章 各國棘EchinocandinsB市場

• 美國
• 加拿大
• 墨西哥
• 巴西
• 英國
• 德國
• 法國
• 俄羅斯
• 義大利
• 西班牙
• 中國
• 印度
• 日本
• 澳洲
• 韓國

19. 美國EchinocandinsB市場

第20章 中國的EchinocandinsB市場

第21章 競爭情勢

• 市場集中度分析，2025年
  • 濃度比（CR）
  • 赫芬達爾-赫希曼指數 (HHI)
• 近期趨勢及影響分析，2025 年
• 2025年產品系列分析
• 基準分析，2025 年
• Amneal Pharmaceuticals, Inc.
• Apotex Inc.
• Astellas Pharma Inc.
• Cipla Limited
• Dr. Reddy's Laboratories Ltd.
• F. Hoffmann-La Roche Ltd.
• Fresenius SE & Co. KGaA
• Gilead Sciences, Inc.
• GlaxoSmithKline plc
• Glenmark Pharmaceuticals Ltd.
• Hikma Pharmaceuticals PLC
• Merck & Co., Inc.
• Novartis AG
• Pfizer Inc.
• Sanofi
• Sun Pharmaceutical Industries Ltd.
• Teva Pharmaceutical Industries Ltd.
• Viatris Inc.
• Wockhardt Limited
• Zydus Lifesciences Limited

The Echinocandin B Market was valued at USD 267.82 million in 2025 and is projected to grow to USD 305.95 million in 2026, with a CAGR of 12.54%, reaching USD 612.34 million by 2032.

KEY MARKET STATISTICS
Base Year [2025]	USD 267.82 million
Estimated Year [2026]	USD 305.95 million
Forecast Year [2032]	USD 612.34 million
CAGR (%)	12.54%

A concise orientation to echinocandin therapy highlighting clinical importance, logistical challenges, and the strategic imperatives for continuity of care

Echinocandins have emerged as a cornerstone in the therapy of serious invasive fungal infections, offering a favorable therapeutic index and targeted activity that complements existing antifungal classes. These agents are integral to contemporary clinical protocols for invasive candidiasis and serve as an important option for select cases of esophageal candidiasis and invasive aspergillosis where treatment complexity demands reliable intravenous therapy. Over the past decade, clinical practice has emphasized stewardship, appropriate use, and rapid diagnostics to optimize outcomes while limiting resistance pressure.

Beyond clinical efficacy, the echinocandin landscape is shaped by manufacturing complexity, parenteral formulation requirements, and regulatory scrutiny surrounding biologic-like drug substances and their generics. Intravenous delivery, cold-chain handling, and reconstitution logistics create operational dependencies across hospitals, ambulatory centers, and specialty clinics. These realities influence procurement practices, tender design, and pharmacy workflow. Consequently, stakeholders must balance clinical imperatives with supply chain resiliency and cost-efficiency.

This introduction frames the subsequent analysis by underscoring the dual imperatives of clinical excellence and operational reliability. The report focuses on actionable insights for clinicians, supply chain managers, and commercial leaders who must navigate evolving therapeutic guidelines, product formulation choices, and distribution complexities to maintain uninterrupted access to echinocandin therapies.

How formulation innovation, tender dynamics, and evolving care pathways are collectively reshaping the production, procurement, and administration of echinocandin therapies

The echinocandin arena is undergoing transformative shifts driven by advances in formulation science, changes in procurement mechanisms, and evolving clinical guidance that together are reshaping how these therapies are produced, purchased, and administered. Recent formulation innovations, including ready-to-reconstitute lyophilized formats and prefilled syringe options, are reducing preparation time and minimizing dosing errors, and they are prompting hospitals and specialty clinics to reassess their inpatient and outpatient infusion practices. As a result, pharmacy teams are increasingly prioritizing products that streamline nursing workflows and reduce room-occupancy times.

Simultaneously, the rise of branded-to-generic transitions across anidulafungin, caspofungin, and micafungin is intensifying competition, which incentivizes manufacturers to differentiate through supply reliability, packaging innovations, and tender responsiveness. Distribution channels are also evolving: hospital pharmacies now balance direct tendering with third-party procurement arrangements, while online and retail pharmacies play expanding roles in outpatient continuity of care. These shifts are occurring in the context of heightened attention to antimicrobial stewardship and rapid diagnostic capabilities that support earlier targeted therapy.

Taken together, these developments are creating new opportunity spaces for strategic partnerships, contract manufacturing, and product modularity that align clinical needs with procurement realities. For organizations that proactively adapt to these transformations, there is potential to enhance treatment consistency and reduce downstream care disruptions.

An integrated assessment of how trade policy adjustments in 2025 have amplified supply chain risks, procurement behaviors, and access priorities across the echinocandin delivery ecosystem

The implementation of United States tariffs in 2025 introduced a pronounced set of cost and logistical pressures that reverberate through the echinocandin supply chain and clinical delivery pathways. At the upstream level, manufacturers faced elevated input costs for active pharmaceutical ingredients and specialized supplies, which in turn pressured production planning and led several contract manufacturers to reassess geographic footprints and supplier diversification strategies. These shifts had immediate implications for lead times and inventory buffers, prompting procurement teams in hospitals and ambulatory centers to place greater emphasis on multi-source qualification and safety stock protocols.

Downstream, hospital pharmacies and tendering bodies encountered increased volatility in unit acquisition costs. Procurement officers responded by intensifying negotiations, favoring tender structures that emphasize supply guarantees and penalties for nonperformance. In parallel, some institutions accelerated efforts to evaluate generic alternatives and ready-to-use formats that could reduce preparation labor and waste, thereby partially offsetting procurement cost pressures. Specialty clinics and outpatient infusion providers also recalibrated contracts with distributors to secure consistent product flow amid fluctuating shipping and customs expenses.

Clinically, access considerations gained prominence as formulary committees balanced cost containment with the imperative to maintain uninterrupted therapy for vulnerable patients. The tariff-driven environment further underscored the importance of strategic stock rotation, cross-facility sharing arrangements, and collaborations with regional suppliers to preserve treatment continuity. Ultimately, the cumulative impact of tariff policy has been to heighten the strategic value of resilient supply chains, contractual agility, and close collaboration between clinical and procurement leadership.

Multidimensional segmentation analysis revealing how product attributes, clinical applications, and distribution choices determine procurement, administration, and clinical outcomes

A granular appraisal of segmentation reveals actionable differentiation across product types, applications, end-user settings, distribution channels, administration routes, formulations, dosage regimens, and packaging formats that collectively influence procurement and clinical decision-making. Within product type, Anidulafungin, Caspofungin, and Micafungin each present distinct clinical positioning and operational profiles, and each is available in branded and generic forms, which affects contracting strategies and formulary placement. Clinicians consider these therapeutic distinctions alongside application contexts that include esophageal candidiasis, invasive aspergillosis, and invasive candidiasis, where disease severity and patient comorbidity profiles guide selection of specific agents and dosing approaches.

End-user segmentation spans ambulatory care centers, hospitals, and specialty clinics, and each setting imposes different priorities: hospitals typically emphasize availability and tender compliance, ambulatory centers prize ease of administration and outpatient continuity, while specialty clinics focus on infusion safety and reimbursement alignment. Distribution channels encompass hospital pharmacy, online pharmacy, and retail pharmacy pathways, with hospital pharmacy procurement further divided between direct tender and third-party tender arrangements, shaping lead times and contractual obligations.

Route of administration is predominantly intravenous and differentiates between continuous infusion and intermittent infusion practices, which in turn affect nursing workload and device selection. Formulation choices, such as lyophilized powder versus prefilled syringe formats, and the further distinction of lyophilized options between manual reconstitution and ready-to-reconstitute systems, directly impact bedside preparation time and aseptic manipulation risk. Dosage regimen segmentation into once daily and twice daily schedules, each with high-dose and standard-dose variants, influences dosing accuracy, pharmacoeconomic assessments, and adherence in outpatient settings. Finally, packaging preferences for multi-dose versus single-dose formats inform waste management, inventory control, and infection prevention measures. By synthesizing these segmentation layers, stakeholders can craft procurement and clinical strategies that align product attributes with care delivery realities.

A regional perspective on how procurement systems, manufacturing footprints, and clinical practice patterns uniquely influence echinocandin availability and care continuity

Regional dynamics materially shape the availability, adoption patterns, and operational approaches to echinocandin therapies, creating differentiated priorities across the Americas, Europe, Middle East & Africa, and Asia-Pacific. In the Americas, hospital-centric care models and centralized procurement frameworks often drive large-scale tendering and a focus on supply reliability, while regulatory alignment and stewardship programs influence prescribing patterns and formulary decisions. These characteristics lead institutions to prioritize robust supplier relationships and contingency planning to mitigate disruptions.

Across Europe, the Middle East & Africa, heterogeneous reimbursement systems and tendering processes produce varied adoption timelines and contracting approaches. In some jurisdictions, centralized tenders and national procurement mechanisms create price sensitivity and emphasize compliance with quality certifications, whereas other regions prioritize local supplier engagement and rapid response capabilities to preserve access in geographically dispersed care networks.

The Asia-Pacific region combines strong manufacturing capacity with rapid uptake of generics and novel distribution models. Production hubs within the region contribute to a complex interplay between export dynamics and domestic supply priorities, while diverse healthcare delivery settings-from tertiary hospitals to community infusion centers-drive differentiated demand for ready-to-use formulations and single-dose packaging. Across all regions, regional regulatory frameworks, logistics infrastructure, and clinical practice patterns determine how product attributes and procurement strategies translate into real-world access and patient care continuity.

Insights into how manufacturers, contract producers, and distributors are competing through supply assurance, formulation differentiation, and value-added service models

Competitive dynamics among manufacturers, contract producers, and distributors are central to shaping supply reliability, product differentiation, and commercial strategy. Innovator firms and established suppliers have focused investments on formulation improvements, supply chain transparency, and tender responsiveness to maintain long-term relationships with hospital chains and procurement consortia. At the same time, generic entrants and contract manufacturing organizations are expanding capacity and pursuing certifications that facilitate inclusion in multiple tender frameworks, thereby increasing sourcing options for large buyers.

Strategic behaviors include pursuing licensing agreements, forming regional distribution partnerships, and offering value-added services such as inventory management, on-site pharmacy training, and product readiness support. Companies that align commercial models with hospital pharmacy workflows by providing ready-to-reconstitute products, prefilled syringes, or simplified dosing guides often gain preference in formularies where preparation time and infection control are high priorities. Additionally, some manufacturers are prioritizing investments in cold-chain logistics and serialized tracking to meet compliance expectations and to demonstrate superior supply assurance.

Given procurement pressures and regulatory expectations, firms are also deploying differentiated tender strategies that combine competitive pricing with contractual guarantees on supply continuity. Those that proactively engage clinical stakeholders to generate real-world evidence and to support stewardship initiatives strengthen their positioning with health systems focused on both outcomes and operational efficiency.

Practical, high-impact recommendations for strengthening procurement agility, clinical alignment, and supply chain resilience in echinocandin therapy delivery

Industry leaders should adopt a multi-pronged strategy that addresses clinical continuity, procurement agility, and supply chain resilience to navigate the evolving echinocandin landscape. First, prioritize supplier diversification and dual-sourcing arrangements to reduce exposure to single points of failure, while negotiating contractual safety nets that include volume flexibility and penalties for nonperformance. Second, invest in formulation and workflow alignment by preferring products that reduce preparation time-such as ready-to-reconstitute lyophilized formats or prefilled syringes-to lower nursing burden and minimize aseptic risk.

Third, strengthen collaboration between clinical, pharmacy, and procurement teams to expedite decision-making and to align tender specifications with therapeutic priorities and administration realities. Fourth, pursue value-based contracting models and outcome-linked agreements where feasible, using real-world evidence to demonstrate clinical and operational benefits that justify premium pricing or preferential placement. Fifth, enhance cold-chain and inventory visibility through serialization and integrated logistics platforms to reduce waste and to improve traceability during shipment and storage.

Finally, develop contingency playbooks that include regional redistribution mechanisms, cross-facility sharing protocols, and engagement plans with regulatory authorities to facilitate expedited approvals or importation during supply stress. These combined actions will improve resilience and create competitive advantage for organizations that must deliver uninterrupted echinocandin therapy across acute and ambulatory care settings.

An evidence-based mixed-methods research approach combining clinician interviews, supply chain mapping, and scenario validation to produce actionable and reproducible findings

The research underpinning this analysis integrated primary qualitative inquiry, systematic secondary review, and scenario-based supply chain mapping to ensure conclusions are robust and actionable. Primary methods included structured interviews with infectious disease specialists, hospital pharmacists, procurement officers, and specialty clinic directors to capture frontline perspectives on clinical preferences, tender dynamics, and administration challenges. These insights were complemented by consultations with logisticians and contract manufacturers to understand production constraints and distribution sensitivities.

Secondary analysis comprised a targeted review of regulatory guidance, clinical practice updates, and publicly available technical documentation on formulation and administration practices. Supply chain mapping involved tracing key nodes from active pharmaceutical ingredient sourcing through final product distribution, identifying critical bottlenecks, and stress-testing these nodes under tariff- and policy-induced disruption scenarios. Data triangulation and validation workshops with subject matter experts refined assumptions and ensured alignment between clinical realities and procurement imperatives.

Finally, the methodology emphasized transparency and reproducibility: data sources and interview protocols were documented, stakeholder feedback was incorporated iteratively, and scenario outputs were reviewed with clinical and supply chain leaders to ensure practical relevance. This mixed-method approach supports the strategic recommendations and operational actions presented throughout the report.

A concise synthesis emphasizing the imperative to align clinical priorities with procurement resilience and operational rigor to sustain echinocandin therapy access

The aggregated analysis underscores a central conclusion: delivering consistent, high-quality echinocandin therapy requires aligning clinical priorities with resilient procurement and adaptable supply chains. Clinical efficacy remains the non-negotiable foundation, but formulation choices, distribution strategies, and procurement mechanisms materially affect whether that efficacy translates into timely patient care. Real-world challenges such as preparation complexity, cold-chain requirements, and tender-driven procurement behaviors necessitate integrated solutions that bridge clinicians, pharmacy operations, and commercial partners.

Moreover, policy and trade developments have amplified the need for proactive risk management, driving organizations to diversify suppliers, enhance inventory visibility, and design tenders that reward supply reliability alongside cost-efficiency. Regional and segment-specific nuances-from hospital-centric demand in some geographies to manufacturing-driven dynamics in others-require tailored approaches rather than one-size-fits-all solutions. By operationalizing recommendations around supplier diversification, formulation alignment, and collaborative contracting, stakeholders can reduce the probability of care disruptions and improve both operational and clinical outcomes.

In sum, strategic foresight, operational rigor, and clinical engagement are the pillars that will determine which organizations successfully navigate the current landscape and maintain uninterrupted access to essential echinocandin therapies.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Definition
• 1.3. Market Segmentation & Coverage
• 1.4. Years Considered for the Study
• 1.5. Currency Considered for the Study
• 1.6. Language Considered for the Study
• 1.7. Key Stakeholders

2. Research Methodology

• 2.1. Introduction
• 2.2. Research Design
  • 2.2.1. Primary Research
  • 2.2.2. Secondary Research
• 2.3. Research Framework
  • 2.3.1. Qualitative Analysis
  • 2.3.2. Quantitative Analysis
• 2.4. Market Size Estimation
  • 2.4.1. Top-Down Approach
  • 2.4.2. Bottom-Up Approach
• 2.5. Data Triangulation
• 2.6. Research Outcomes
• 2.7. Research Assumptions
• 2.8. Research Limitations

3. Executive Summary

• 3.1. Introduction
• 3.2. CXO Perspective
• 3.3. Market Size & Growth Trends
• 3.4. Market Share Analysis, 2025
• 3.5. FPNV Positioning Matrix, 2025
• 3.6. New Revenue Opportunities
• 3.7. Next-Generation Business Models
• 3.8. Industry Roadmap

4. Market Overview

• 4.1. Introduction
• 4.2. Industry Ecosystem & Value Chain Analysis
  • 4.2.1. Supply-Side Analysis
  • 4.2.2. Demand-Side Analysis
  • 4.2.3. Stakeholder Analysis
• 4.3. Porter's Five Forces Analysis
• 4.4. PESTLE Analysis
• 4.5. Market Outlook
  • 4.5.1. Near-Term Market Outlook (0-2 Years)
  • 4.5.2. Medium-Term Market Outlook (3-5 Years)
  • 4.5.3. Long-Term Market Outlook (5-10 Years)
• 4.6. Go-to-Market Strategy

5. Market Insights

• 5.1. Consumer Insights & End-User Perspective
• 5.2. Consumer Experience Benchmarking
• 5.3. Opportunity Mapping
• 5.4. Distribution Channel Analysis
• 5.5. Pricing Trend Analysis
• 5.6. Regulatory Compliance & Standards Framework
• 5.7. ESG & Sustainability Analysis
• 5.8. Disruption & Risk Scenarios
• 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Echinocandin B Market, by Product Type

• 8.1. Active Pharmaceutical Ingredient (API)
  • 8.1.1. Crude Echinocandin B
  • 8.1.2. Purified Echinocandin B
• 8.2. Intermediate For Derivatives
  • 8.2.1. Caspofungin Intermediate
  • 8.2.2. Micafungin Intermediate
  • 8.2.3. Anidulafungin Intermediate
• 8.3. Finished Dosage Form
  • 8.3.1. Injectable Formulations
  • 8.3.2. Oral Formulations
• 8.4. Reference Standard
• 8.5. Custom Synthesis

9. Echinocandin B Market, by Route Of Administration

• 9.1. Intravenous
  • 9.1.1. Continuous Infusion
  • 9.1.2. Intermittent Infusion

10. Echinocandin B Market, by Formulation

• 10.1. Lyophilized Powder
  • 10.1.1. Manual Reconstitution
  • 10.1.2. Ready To Reconstitute
• 10.2. Prefilled Syringe

11. Echinocandin B Market, by Dosage Regimen

• 11.1. Once Daily
  • 11.1.1. High Dose
  • 11.1.2. Standard Dose
• 11.2. Twice Daily
  • 11.2.1. High Dose
  • 11.2.2. Standard Dose

12. Echinocandin B Market, by Packaging

• 12.1. Multi Dose Packaging
• 12.2. Single Dose Packaging

13. Echinocandin B Market, by Distribution Channel

• 13.1. Hospital Pharmacy
  • 13.1.1. Direct Tender
  • 13.1.2. Third Party Tender
• 13.2. Online Pharmacy
• 13.3. Retail Pharmacy

14. Echinocandin B Market, by Application

• 14.1. Therapeutic Development
  • 14.1.1. Antifungal Drug Development
  • 14.1.2. Combination Therapy Development
• 14.2. Commercial Production
  • 14.2.1. Bulk Drug Manufacturing
  • 14.2.2. Formulation Manufacturing
• 14.3. Research & Development
  • 14.3.1. Mechanistic Studies
  • 14.3.2. Resistance Profiling
  • 14.3.3. Pharmacokinetic Studies
  • 14.3.4. Toxicology Studies
• 14.4. Quality Control & Analytics
  • 14.4.1. Reference Standards
  • 14.4.2. Assay Calibration
  • 14.4.3. Stability Testing
• 14.5. Diagnostic Use
  • 14.5.1. Fungal Susceptibility Testing
  • 14.5.2. Biomarker Assay Development

15. Echinocandin B Market, by End User

• 15.1. Pharmaceutical & Biotechnology Companies
  • 15.1.1. Branded Drug Manufacturers
  • 15.1.2. Generic Drug Manufacturers
  • 15.1.3. Contract Manufacturing Organizations
• 15.2. Contract Research Organizations
• 15.3. Academic & Research Institutes
• 15.4. Diagnostic Laboratories
• 15.5. Government & Nonprofit Research Bodies

16. Echinocandin B Market, by Region

• 16.1. Americas
  • 16.1.1. North America
  • 16.1.2. Latin America
• 16.2. Europe, Middle East & Africa
  • 16.2.1. Europe
  • 16.2.2. Middle East
  • 16.2.3. Africa
• 16.3. Asia-Pacific

17. Echinocandin B Market, by Group

• 17.1. ASEAN
• 17.2. GCC
• 17.3. European Union
• 17.4. BRICS
• 17.5. G7
• 17.6. NATO

18. Echinocandin B Market, by Country

• 18.1. United States
• 18.2. Canada
• 18.3. Mexico
• 18.4. Brazil
• 18.5. United Kingdom
• 18.6. Germany
• 18.7. France
• 18.8. Russia
• 18.9. Italy
• 18.10. Spain
• 18.11. China
• 18.12. India
• 18.13. Japan
• 18.14. Australia
• 18.15. South Korea

19. United States Echinocandin B Market

20. China Echinocandin B Market

21. Competitive Landscape

• 21.1. Market Concentration Analysis, 2025
  • 21.1.1. Concentration Ratio (CR)
  • 21.1.2. Herfindahl Hirschman Index (HHI)
• 21.2. Recent Developments & Impact Analysis, 2025
• 21.3. Product Portfolio Analysis, 2025
• 21.4. Benchmarking Analysis, 2025
• 21.5. Amneal Pharmaceuticals, Inc.
• 21.6. Apotex Inc.
• 21.7. Astellas Pharma Inc.
• 21.8. Cipla Limited
• 21.9. Dr. Reddy's Laboratories Ltd.
• 21.10. F. Hoffmann-La Roche Ltd.
• 21.11. Fresenius SE & Co. KGaA
• 21.12. Gilead Sciences, Inc.
• 21.13. GlaxoSmithKline plc
• 21.14. Glenmark Pharmaceuticals Ltd.
• 21.15. Hikma Pharmaceuticals PLC
• 21.16. Merck & Co., Inc.
• 21.17. Novartis AG
• 21.18. Pfizer Inc.
• 21.19. Sanofi
• 21.20. Sun Pharmaceutical Industries Ltd.
• 21.21. Teva Pharmaceutical Industries Ltd.
• 21.22. Viatris Inc.
• 21.23. Wockhardt Limited
• 21.24. Zydus Lifesciences Limited

LIST OF FIGURES

• FIGURE 1. GLOBAL ECHINOCANDIN B MARKET SIZE, 2018-2032 (USD MILLION)
• FIGURE 2. GLOBAL ECHINOCANDIN B MARKET SHARE, BY KEY PLAYER, 2025
• FIGURE 3. GLOBAL ECHINOCANDIN B MARKET, FPNV POSITIONING MATRIX, 2025
• FIGURE 4. GLOBAL ECHINOCANDIN B MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
• FIGURE 5. GLOBAL ECHINOCANDIN B MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
• FIGURE 6. GLOBAL ECHINOCANDIN B MARKET SIZE, BY FORMULATION, 2025 VS 2026 VS 2032 (USD MILLION)
• FIGURE 7. GLOBAL ECHINOCANDIN B MARKET SIZE, BY DOSAGE REGIMEN, 2025 VS 2026 VS 2032 (USD MILLION)
• FIGURE 8. GLOBAL ECHINOCANDIN B MARKET SIZE, BY PACKAGING, 2025 VS 2026 VS 2032 (USD MILLION)
• FIGURE 9. GLOBAL ECHINOCANDIN B MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
• FIGURE 10. GLOBAL ECHINOCANDIN B MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
• FIGURE 11. GLOBAL ECHINOCANDIN B MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
• FIGURE 12. GLOBAL ECHINOCANDIN B MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
• FIGURE 13. GLOBAL ECHINOCANDIN B MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
• FIGURE 14. GLOBAL ECHINOCANDIN B MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
• FIGURE 15. UNITED STATES ECHINOCANDIN B MARKET SIZE, 2018-2032 (USD MILLION)
• FIGURE 16. CHINA ECHINOCANDIN B MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

• TABLE 1. GLOBAL ECHINOCANDIN B MARKET SIZE, 2018-2032 (USD MILLION)
• TABLE 2. GLOBAL ECHINOCANDIN B MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
• TABLE 3. GLOBAL ECHINOCANDIN B MARKET SIZE, BY ACTIVE PHARMACEUTICAL INGREDIENT (API), BY REGION, 2018-2032 (USD MILLION)
• TABLE 4. GLOBAL ECHINOCANDIN B MARKET SIZE, BY ACTIVE PHARMACEUTICAL INGREDIENT (API), BY GROUP, 2018-2032 (USD MILLION)
• TABLE 5. GLOBAL ECHINOCANDIN B MARKET SIZE, BY ACTIVE PHARMACEUTICAL INGREDIENT (API), BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 6. GLOBAL ECHINOCANDIN B MARKET SIZE, BY ACTIVE PHARMACEUTICAL INGREDIENT (API), 2018-2032 (USD MILLION)
• TABLE 7. GLOBAL ECHINOCANDIN B MARKET SIZE, BY CRUDE ECHINOCANDIN B, BY REGION, 2018-2032 (USD MILLION)
• TABLE 8. GLOBAL ECHINOCANDIN B MARKET SIZE, BY CRUDE ECHINOCANDIN B, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 9. GLOBAL ECHINOCANDIN B MARKET SIZE, BY CRUDE ECHINOCANDIN B, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 10. GLOBAL ECHINOCANDIN B MARKET SIZE, BY PURIFIED ECHINOCANDIN B, BY REGION, 2018-2032 (USD MILLION)
• TABLE 11. GLOBAL ECHINOCANDIN B MARKET SIZE, BY PURIFIED ECHINOCANDIN B, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 12. GLOBAL ECHINOCANDIN B MARKET SIZE, BY PURIFIED ECHINOCANDIN B, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 13. GLOBAL ECHINOCANDIN B MARKET SIZE, BY INTERMEDIATE FOR DERIVATIVES, BY REGION, 2018-2032 (USD MILLION)
• TABLE 14. GLOBAL ECHINOCANDIN B MARKET SIZE, BY INTERMEDIATE FOR DERIVATIVES, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 15. GLOBAL ECHINOCANDIN B MARKET SIZE, BY INTERMEDIATE FOR DERIVATIVES, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 16. GLOBAL ECHINOCANDIN B MARKET SIZE, BY INTERMEDIATE FOR DERIVATIVES, 2018-2032 (USD MILLION)
• TABLE 17. GLOBAL ECHINOCANDIN B MARKET SIZE, BY CASPOFUNGIN INTERMEDIATE, BY REGION, 2018-2032 (USD MILLION)
• TABLE 18. GLOBAL ECHINOCANDIN B MARKET SIZE, BY CASPOFUNGIN INTERMEDIATE, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 19. GLOBAL ECHINOCANDIN B MARKET SIZE, BY CASPOFUNGIN INTERMEDIATE, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 20. GLOBAL ECHINOCANDIN B MARKET SIZE, BY MICAFUNGIN INTERMEDIATE, BY REGION, 2018-2032 (USD MILLION)
• TABLE 21. GLOBAL ECHINOCANDIN B MARKET SIZE, BY MICAFUNGIN INTERMEDIATE, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 22. GLOBAL ECHINOCANDIN B MARKET SIZE, BY MICAFUNGIN INTERMEDIATE, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 23. GLOBAL ECHINOCANDIN B MARKET SIZE, BY ANIDULAFUNGIN INTERMEDIATE, BY REGION, 2018-2032 (USD MILLION)
• TABLE 24. GLOBAL ECHINOCANDIN B MARKET SIZE, BY ANIDULAFUNGIN INTERMEDIATE, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 25. GLOBAL ECHINOCANDIN B MARKET SIZE, BY ANIDULAFUNGIN INTERMEDIATE, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 26. GLOBAL ECHINOCANDIN B MARKET SIZE, BY FINISHED DOSAGE FORM, BY REGION, 2018-2032 (USD MILLION)
• TABLE 27. GLOBAL ECHINOCANDIN B MARKET SIZE, BY FINISHED DOSAGE FORM, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 28. GLOBAL ECHINOCANDIN B MARKET SIZE, BY FINISHED DOSAGE FORM, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 29. GLOBAL ECHINOCANDIN B MARKET SIZE, BY FINISHED DOSAGE FORM, 2018-2032 (USD MILLION)
• TABLE 30. GLOBAL ECHINOCANDIN B MARKET SIZE, BY INJECTABLE FORMULATIONS, BY REGION, 2018-2032 (USD MILLION)
• TABLE 31. GLOBAL ECHINOCANDIN B MARKET SIZE, BY INJECTABLE FORMULATIONS, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 32. GLOBAL ECHINOCANDIN B MARKET SIZE, BY INJECTABLE FORMULATIONS, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 33. GLOBAL ECHINOCANDIN B MARKET SIZE, BY ORAL FORMULATIONS, BY REGION, 2018-2032 (USD MILLION)
• TABLE 34. GLOBAL ECHINOCANDIN B MARKET SIZE, BY ORAL FORMULATIONS, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 35. GLOBAL ECHINOCANDIN B MARKET SIZE, BY ORAL FORMULATIONS, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 36. GLOBAL ECHINOCANDIN B MARKET SIZE, BY REFERENCE STANDARD, BY REGION, 2018-2032 (USD MILLION)
• TABLE 37. GLOBAL ECHINOCANDIN B MARKET SIZE, BY REFERENCE STANDARD, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 38. GLOBAL ECHINOCANDIN B MARKET SIZE, BY REFERENCE STANDARD, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 39. GLOBAL ECHINOCANDIN B MARKET SIZE, BY CUSTOM SYNTHESIS, BY REGION, 2018-2032 (USD MILLION)
• TABLE 40. GLOBAL ECHINOCANDIN B MARKET SIZE, BY CUSTOM SYNTHESIS, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 41. GLOBAL ECHINOCANDIN B MARKET SIZE, BY CUSTOM SYNTHESIS, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 42. GLOBAL ECHINOCANDIN B MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
• TABLE 43. GLOBAL ECHINOCANDIN B MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2032 (USD MILLION)
• TABLE 44. GLOBAL ECHINOCANDIN B MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 45. GLOBAL ECHINOCANDIN B MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 46. GLOBAL ECHINOCANDIN B MARKET SIZE, BY INTRAVENOUS, 2018-2032 (USD MILLION)
• TABLE 47. GLOBAL ECHINOCANDIN B MARKET SIZE, BY CONTINUOUS INFUSION, BY REGION, 2018-2032 (USD MILLION)
• TABLE 48. GLOBAL ECHINOCANDIN B MARKET SIZE, BY CONTINUOUS INFUSION, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 49. GLOBAL ECHINOCANDIN B MARKET SIZE, BY CONTINUOUS INFUSION, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 50. GLOBAL ECHINOCANDIN B MARKET SIZE, BY INTERMITTENT INFUSION, BY REGION, 2018-2032 (USD MILLION)
• TABLE 51. GLOBAL ECHINOCANDIN B MARKET SIZE, BY INTERMITTENT INFUSION, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 52. GLOBAL ECHINOCANDIN B MARKET SIZE, BY INTERMITTENT INFUSION, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 53. GLOBAL ECHINOCANDIN B MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
• TABLE 54. GLOBAL ECHINOCANDIN B MARKET SIZE, BY LYOPHILIZED POWDER, BY REGION, 2018-2032 (USD MILLION)
• TABLE 55. GLOBAL ECHINOCANDIN B MARKET SIZE, BY LYOPHILIZED POWDER, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 56. GLOBAL ECHINOCANDIN B MARKET SIZE, BY LYOPHILIZED POWDER, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 57. GLOBAL ECHINOCANDIN B MARKET SIZE, BY LYOPHILIZED POWDER, 2018-2032 (USD MILLION)
• TABLE 58. GLOBAL ECHINOCANDIN B MARKET SIZE, BY MANUAL RECONSTITUTION, BY REGION, 2018-2032 (USD MILLION)
• TABLE 59. GLOBAL ECHINOCANDIN B MARKET SIZE, BY MANUAL RECONSTITUTION, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 60. GLOBAL ECHINOCANDIN B MARKET SIZE, BY MANUAL RECONSTITUTION, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 61. GLOBAL ECHINOCANDIN B MARKET SIZE, BY READY TO RECONSTITUTE, BY REGION, 2018-2032 (USD MILLION)
• TABLE 62. GLOBAL ECHINOCANDIN B MARKET SIZE, BY READY TO RECONSTITUTE, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 63. GLOBAL ECHINOCANDIN B MARKET SIZE, BY READY TO RECONSTITUTE, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 64. GLOBAL ECHINOCANDIN B MARKET SIZE, BY PREFILLED SYRINGE, BY REGION, 2018-2032 (USD MILLION)
• TABLE 65. GLOBAL ECHINOCANDIN B MARKET SIZE, BY PREFILLED SYRINGE, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 66. GLOBAL ECHINOCANDIN B MARKET SIZE, BY PREFILLED SYRINGE, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 67. GLOBAL ECHINOCANDIN B MARKET SIZE, BY DOSAGE REGIMEN, 2018-2032 (USD MILLION)
• TABLE 68. GLOBAL ECHINOCANDIN B MARKET SIZE, BY ONCE DAILY, BY REGION, 2018-2032 (USD MILLION)
• TABLE 69. GLOBAL ECHINOCANDIN B MARKET SIZE, BY ONCE DAILY, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 70. GLOBAL ECHINOCANDIN B MARKET SIZE, BY ONCE DAILY, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 71. GLOBAL ECHINOCANDIN B MARKET SIZE, BY ONCE DAILY, 2018-2032 (USD MILLION)
• TABLE 72. GLOBAL ECHINOCANDIN B MARKET SIZE, BY HIGH DOSE, BY REGION, 2018-2032 (USD MILLION)
• TABLE 73. GLOBAL ECHINOCANDIN B MARKET SIZE, BY HIGH DOSE, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 74. GLOBAL ECHINOCANDIN B MARKET SIZE, BY HIGH DOSE, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 75. GLOBAL ECHINOCANDIN B MARKET SIZE, BY STANDARD DOSE, BY REGION, 2018-2032 (USD MILLION)
• TABLE 76. GLOBAL ECHINOCANDIN B MARKET SIZE, BY STANDARD DOSE, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 77. GLOBAL ECHINOCANDIN B MARKET SIZE, BY STANDARD DOSE, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 78. GLOBAL ECHINOCANDIN B MARKET SIZE, BY TWICE DAILY, BY REGION, 2018-2032 (USD MILLION)
• TABLE 79. GLOBAL ECHINOCANDIN B MARKET SIZE, BY TWICE DAILY, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 80. GLOBAL ECHINOCANDIN B MARKET SIZE, BY TWICE DAILY, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 81. GLOBAL ECHINOCANDIN B MARKET SIZE, BY TWICE DAILY, 2018-2032 (USD MILLION)
• TABLE 82. GLOBAL ECHINOCANDIN B MARKET SIZE, BY HIGH DOSE, BY REGION, 2018-2032 (USD MILLION)
• TABLE 83. GLOBAL ECHINOCANDIN B MARKET SIZE, BY HIGH DOSE, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 84. GLOBAL ECHINOCANDIN B MARKET SIZE, BY HIGH DOSE, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 85. GLOBAL ECHINOCANDIN B MARKET SIZE, BY STANDARD DOSE, BY REGION, 2018-2032 (USD MILLION)
• TABLE 86. GLOBAL ECHINOCANDIN B MARKET SIZE, BY STANDARD DOSE, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 87. GLOBAL ECHINOCANDIN B MARKET SIZE, BY STANDARD DOSE, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 88. GLOBAL ECHINOCANDIN B MARKET SIZE, BY PACKAGING, 2018-2032 (USD MILLION)
• TABLE 89. GLOBAL ECHINOCANDIN B MARKET SIZE, BY MULTI DOSE PACKAGING, BY REGION, 2018-2032 (USD MILLION)
• TABLE 90. GLOBAL ECHINOCANDIN B MARKET SIZE, BY MULTI DOSE PACKAGING, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 91. GLOBAL ECHINOCANDIN B MARKET SIZE, BY MULTI DOSE PACKAGING, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 92. GLOBAL ECHINOCANDIN B MARKET SIZE, BY SINGLE DOSE PACKAGING, BY REGION, 2018-2032 (USD MILLION)
• TABLE 93. GLOBAL ECHINOCANDIN B MARKET SIZE, BY SINGLE DOSE PACKAGING, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 94. GLOBAL ECHINOCANDIN B MARKET SIZE, BY SINGLE DOSE PACKAGING, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 95. GLOBAL ECHINOCANDIN B MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
• TABLE 96. GLOBAL ECHINOCANDIN B MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2032 (USD MILLION)
• TABLE 97. GLOBAL ECHINOCANDIN B MARKET SIZE, BY HOSPITAL PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 98. GLOBAL ECHINOCANDIN B MARKET SIZE, BY HOSPITAL PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 99. GLOBAL ECHINOCANDIN B MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2032 (USD MILLION)
• TABLE 100. GLOBAL ECHINOCANDIN B MARKET SIZE, BY DIRECT TENDER, BY REGION, 2018-2032 (USD MILLION)
• TABLE 101. GLOBAL ECHINOCANDIN B MARKET SIZE, BY DIRECT TENDER, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 102. GLOBAL ECHINOCANDIN B MARKET SIZE, BY DIRECT TENDER, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 103. GLOBAL ECHINOCANDIN B MARKET SIZE, BY THIRD PARTY TENDER, BY REGION, 2018-2032 (USD MILLION)
• TABLE 104. GLOBAL ECHINOCANDIN B MARKET SIZE, BY THIRD PARTY TENDER, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 105. GLOBAL ECHINOCANDIN B MARKET SIZE, BY THIRD PARTY TENDER, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 106. GLOBAL ECHINOCANDIN B MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2032 (USD MILLION)
• TABLE 107. GLOBAL ECHINOCANDIN B MARKET SIZE, BY ONLINE PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 108. GLOBAL ECHINOCANDIN B MARKET SIZE, BY ONLINE PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 109. GLOBAL ECHINOCANDIN B MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2032 (USD MILLION)
• TABLE 110. GLOBAL ECHINOCANDIN B MARKET SIZE, BY RETAIL PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 111. GLOBAL ECHINOCANDIN B MARKET SIZE, BY RETAIL PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 112. GLOBAL ECHINOCANDIN B MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
• TABLE 113. GLOBAL ECHINOCANDIN B MARKET SIZE, BY THERAPEUTIC DEVELOPMENT, BY REGION, 2018-2032 (USD MILLION)
• TABLE 114. GLOBAL ECHINOCANDIN B MARKET SIZE, BY THERAPEUTIC DEVELOPMENT, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 115. GLOBAL ECHINOCANDIN B MARKET SIZE, BY THERAPEUTIC DEVELOPMENT, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 116. GLOBAL ECHINOCANDIN B MARKET SIZE, BY THERAPEUTIC DEVELOPMENT, 2018-2032 (USD MILLION)
• TABLE 117. GLOBAL ECHINOCANDIN B MARKET SIZE, BY ANTIFUNGAL DRUG DEVELOPMENT, BY REGION, 2018-2032 (USD MILLION)
• TABLE 118. GLOBAL ECHINOCANDIN B MARKET SIZE, BY ANTIFUNGAL DRUG DEVELOPMENT, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 119. GLOBAL ECHINOCANDIN B MARKET SIZE, BY ANTIFUNGAL DRUG DEVELOPMENT, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 120. GLOBAL ECHINOCANDIN B MARKET SIZE, BY COMBINATION THERAPY DEVELOPMENT, BY REGION, 2018-2032 (USD MILLION)
• TABLE 121. GLOBAL ECHINOCANDIN B MARKET SIZE, BY COMBINATION THERAPY DEVELOPMENT, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 122. GLOBAL ECHINOCANDIN B MARKET SIZE, BY COMBINATION THERAPY DEVELOPMENT, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 123. GLOBAL ECHINOCANDIN B MARKET SIZE, BY COMMERCIAL PRODUCTION, BY REGION, 2018-2032 (USD MILLION)
• TABLE 124. GLOBAL ECHINOCANDIN B MARKET SIZE, BY COMMERCIAL PRODUCTION, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 125. GLOBAL ECHINOCANDIN B MARKET SIZE, BY COMMERCIAL PRODUCTION, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 126. GLOBAL ECHINOCANDIN B MARKET SIZE, BY COMMERCIAL PRODUCTION, 2018-2032 (USD MILLION)
• TABLE 127. GLOBAL ECHINOCANDIN B MARKET SIZE, BY BULK DRUG MANUFACTURING, BY REGION, 2018-2032 (USD MILLION)
• TABLE 128. GLOBAL ECHINOCANDIN B MARKET SIZE, BY BULK DRUG MANUFACTURING, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 129. GLOBAL ECHINOCANDIN B MARKET SIZE, BY BULK DRUG MANUFACTURING, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 130. GLOBAL ECHINOCANDIN B MARKET SIZE, BY FORMULATION MANUFACTURING, BY REGION, 2018-2032 (USD MILLION)
• TABLE 131. GLOBAL ECHINOCANDIN B MARKET SIZE, BY FORMULATION MANUFACTURING, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 132. GLOBAL ECHINOCANDIN B MARKET SIZE, BY FORMULATION MANUFACTURING, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 133. GLOBAL ECHINOCANDIN B MARKET SIZE, BY RESEARCH & DEVELOPMENT, BY REGION, 2018-2032 (USD MILLION)
• TABLE 134. GLOBAL ECHINOCANDIN B MARKET SIZE, BY RESEARCH & DEVELOPMENT, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 135. GLOBAL ECHINOCANDIN B MARKET SIZE, BY RESEARCH & DEVELOPMENT, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 136. GLOBAL ECHINOCANDIN B MARKET SIZE, BY RESEARCH & DEVELOPMENT, 2018-2032 (USD MILLION)
• TABLE 137. GLOBAL ECHINOCANDIN B MARKET SIZE, BY MECHANISTIC STUDIES, BY REGION, 2018-2032 (USD MILLION)
• TABLE 138. GLOBAL ECHINOCANDIN B MARKET SIZE, BY MECHANISTIC STUDIES, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 139. GLOBAL ECHINOCANDIN B MARKET SIZE, BY MECHANISTIC STUDIES, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 140. GLOBAL ECHINOCANDIN B MARKET SIZE, BY RESISTANCE PROFILING, BY REGION, 2018-2032 (USD MILLION)
• TABLE 141. GLOBAL ECHINOCANDIN B MARKET SIZE, BY RESISTANCE PROFILING, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 142. GLOBAL ECHINOCANDIN B MARKET SIZE, BY RESISTANCE PROFILING, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 143. GLOBAL ECHINOCANDIN B MARKET SIZE, BY PHARMACOKINETIC STUDIES, BY REGION, 2018-2032 (USD MILLION)
• TABLE 144. GLOBAL ECHINOCANDIN B MARKET SIZE, BY PHARMACOKINETIC STUDIES, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 145. GLOBAL ECHINOCANDIN B MARKET SIZE, BY PHARMACOKINETIC STUDIES, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 146. GLOBAL ECHINOCANDIN B MARKET SIZE, BY TOXICOLOGY STUDIES, BY REGION, 2018-2032 (USD MILLION)
• TABLE 147. GLOBAL ECHINOCANDIN B MARKET SIZE, BY TOXICOLOGY STUDIES, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 148. GLOBAL ECHINOCANDIN B MARKET SIZE, BY TOXICOLOGY STUDIES, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 149. GLOBAL ECHINOCANDIN B MARKET SIZE, BY QUALITY CONTROL & ANALYTICS, BY REGION, 2018-2032 (USD MILLION)
• TABLE 150. GLOBAL ECHINOCANDIN B MARKET SIZE, BY QUALITY CONTROL & ANALYTICS, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 151. GLOBAL ECHINOCANDIN B MARKET SIZE, BY QUALITY CONTROL & ANALYTICS, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 152. GLOBAL ECHINOCANDIN B MARKET SIZE, BY QUALITY CONTROL & ANALYTICS, 2018-2032 (USD MILLION)
• TABLE 153. GLOBAL ECHINOCANDIN B MARKET SIZE, BY REFERENCE STANDARDS, BY REGION, 2018-2032 (USD MILLION)
• TABLE 154. GLOBAL ECHINOCANDIN B MARKET SIZE, BY REFERENCE STANDARDS, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 155. GLOBAL ECHINOCANDIN B MARKET SIZE, BY REFERENCE STANDARDS, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 156. GLOBAL ECHINOCANDIN B MARKET SIZE, BY ASSAY CALIBRATION, BY REGION, 2018-2032 (USD MILLION)
• TABLE 157. GLOBAL ECHINOCANDIN B MARKET SIZE, BY ASSAY CALIBRATION, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 158. GLOBAL ECHINOCANDIN B MARKET SIZE, BY ASSAY CALIBRATION, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 159. GLOBAL ECHINOCANDIN B MARKET SIZE, BY STABILITY TESTING, BY REGION, 2018-2032 (USD MILLION)
• TABLE 160. GLOBAL ECHINOCANDIN B MARKET SIZE, BY STABILITY TESTING, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 161. GLOBAL ECHINOCANDIN B MARKET SIZE, BY STABILITY TESTING, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 162. GLOBAL ECHINOCANDIN B MARKET SIZE, BY DIAGNOSTIC USE, BY REGION, 2018-2032 (USD MILLION)
• TABLE 163. GLOBAL ECHINOCANDIN B MARKET SIZE, BY DIAGNOSTIC USE, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 164. GLOBAL ECHINOCANDIN B MARKET SIZE, BY DIAGNOSTIC USE, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 165. GLOBAL ECHINOCANDIN B MARKET SIZE, BY DIAGNOSTIC USE, 2018-2032 (USD MILLION)
• TABLE 166. GLOBAL ECHINOCANDIN B MARKET SIZE, BY FUNGAL SUSCEPTIBILITY TESTING, BY REGION, 2018-2032 (USD MILLION)
• TABLE 167. GLOBAL ECHINOCANDIN B MARKET SIZE, BY FUNGAL SUSCEPTIBILITY TESTING, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 168. GLOBAL ECHINOCANDIN B MARKET SIZE, BY FUNGAL SUSCEPTIBILITY TESTING, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 169. GLOBAL ECHINOCANDIN B MARKET SIZE, BY BIOMARKER ASSAY DEVELOPMENT, BY REGION, 2018-2032 (USD MILLION)
• TABLE 170. GLOBAL ECHINOCANDIN B MARKET SIZE, BY BIOMARKER ASSAY DEVELOPMENT, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 171. GLOBAL ECHINOCANDIN B MARKET SIZE, BY BIOMARKER ASSAY DEVELOPMENT, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 172. GLOBAL ECHINOCANDIN B MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
• TABLE 173. GLOBAL ECHINOCANDIN B MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2018-2032 (USD MILLION)
• TABLE 174. GLOBAL ECHINOCANDIN B MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 175. GLOBAL ECHINOCANDIN B MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 176. GLOBAL ECHINOCANDIN B MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, 2018-2032 (USD MILLION)
• TABLE 177. GLOBAL ECHINOCANDIN B MARKET SIZE, BY BRANDED DRUG MANUFACTURERS, BY REGION, 2018-2032 (USD MILLION)
• TABLE 178. GLOBAL ECHINOCANDIN B MARKET SIZE, BY BRANDED DRUG MANUFACTURERS, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 179. GLOBAL ECHINOCANDIN B MARKET SIZE, BY BRANDED DRUG MANUFACTURERS, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 180. GLOBAL ECHINOCANDIN B MARKET SIZE, BY GENERIC DRUG MANUFACTURERS, BY REGION, 2018-2032 (USD MILLION)
• TABLE 181. GLOBAL ECHINOCANDIN B MARKET SIZE, BY GENERIC DRUG MANUFACTURERS, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 182. GLOBAL ECHINOCANDIN B MARKET SIZE, BY GENERIC DRUG MANUFACTURERS, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 183. GLOBAL ECHINOCANDIN B MARKET SIZE, BY CONTRACT MANUFACTURING ORGANIZATIONS, BY REGION, 2018-2032 (USD MILLION)
• TABLE 184. GLOBAL ECHINOCANDIN B MARKET SIZE, BY CONTRACT MANUFACTURING ORGANIZATIONS, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 185. GLOBAL ECHINOCANDIN B MARKET SIZE, BY CONTRACT MANUFACTURING ORGANIZATIONS, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 186. GLOBAL ECHINOCANDIN B MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2018-2032 (USD MILLION)
• TABLE 187. GLOBAL ECHINOCANDIN B MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 188. GLOBAL ECHINOCANDIN B MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 189. GLOBAL ECHINOCANDIN B MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2018-2032 (USD MILLION)
• TABLE 190. GLOBAL ECHINOCANDIN B MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 191. GLOBAL ECHINOCANDIN B MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 192. GLOBAL ECHINOCANDIN B MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2018-2032 (USD MILLION)
• TABLE 193. GLOBAL ECHINOCANDIN B MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 194. GLOBAL ECHINOCANDIN B MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 195. GLOBAL ECHINOCANDIN B MARKET SIZE, BY GOVERNMENT & NONPROFIT RESEARCH BODIES, BY REGION, 2018-2032 (USD MILLION)
• TABLE 196. GLOBAL ECHINOCANDIN B MARKET SIZE, BY GOVERNMENT & NONPROFIT RESEARCH BODIES, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 197. GLOBAL ECHINOCANDIN B MARKET SIZE, BY GOVERNMENT & NONPROFIT RESEARCH BODIES, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 198. GLOBAL ECHINOCANDIN B MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
• TABLE 199. AMERICAS ECHINOCANDIN B MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
• TABLE 200. AMERICAS ECHINOCANDIN B MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
• TABLE 201. AMERICAS ECHINOCANDIN B MARKET SIZE, BY ACTIVE PHARMACEUTICAL INGREDIENT (API), 2018-2032 (USD MILLION)
• TABLE 202. AMERICAS ECHINOCANDIN B MARKET SIZE, BY INTERMEDIATE FOR DERIVATIVES, 2018-2032 (USD MILLION)
• TABLE 203. AMERICAS ECHINOCANDIN B MARKET SIZE, BY FINISHED DOSAGE FORM, 2018-2032 (USD MILLION)
• TABLE 204. AMERICAS ECHINOCANDIN B MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
• TABLE 205. AMERICAS ECHINOCANDIN B MARKET SIZE, BY INTRAVENOUS, 2018-2032 (USD MILLION)
• TABLE 206. AMERICAS ECHINOCANDIN B MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
• TABLE 207. AMERICAS ECHINOCANDIN B MARKET SIZE, BY LYOPHILIZED POWDER, 2018-2032 (USD MILLION)
• TABLE 208. AMERICAS ECHINOCANDIN B MARKET SIZE, BY DOSAGE REGIMEN, 2018-2032 (USD MILLION)
• TABLE 209. AMERICAS ECHINOCANDIN B MARKET SIZE, BY ONCE DAILY, 2018-2032 (USD MILLION)
• TABLE 210. AMERICAS ECHINOCANDIN B MARKET SIZE, BY TWICE DAILY, 2018-2032 (USD MILLION)
• TABLE 211. AMERICAS ECHINOCANDIN B MARKET SIZE, BY PACKAGING, 2018-2032 (USD MILLION)
• TABLE 212. AMERICAS ECHINOCANDIN B MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
• TABLE 213. AMERICAS ECHINOCANDIN B MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2032 (USD MILLION)
• TABLE 214. AMERICAS ECHINOCANDIN B MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
• TABLE 215. AMERICAS ECHINOCANDIN B MARKET SIZE, BY THERAPEUTIC DEVELOPMENT, 2018-2032 (USD MILLION)
• TABLE 216. AMERICAS ECHINOCANDIN B MARKET SIZE, BY COMMERCIAL PRODUCTION, 2018-2032 (USD MILLION)
• TABLE 217. AMERICAS ECHINOCANDIN B MARKET SIZE, BY RESEARCH & DEVELOPMENT, 2018-2032 (USD MILLION)
• TABLE 218. AMERICAS ECHINOCANDIN B MARKET SIZE, BY QUALITY CONTROL & ANALYTICS, 2018-2032 (USD MILLION)
• TABLE 219. AMERICAS ECHINOCANDIN B MARKET SIZE, BY DIAGNOSTIC USE, 2018-2032 (USD MILLION)
• TABLE 220. AMERICAS ECHINOCANDIN B MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
• TABLE 221. AMERICAS ECHINOCANDIN B MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, 2018-2032 (USD MILLION)
• TABLE 222. NORTH AMERICA ECHINOCANDIN B MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 223. NORTH AMERICA ECHINOCANDIN B MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
• TABLE 224. NORTH AMERICA ECHINOCANDIN B MARKET SIZE, BY ACTIVE PHARMACEUTICAL INGREDIENT (API), 2018-2032 (USD MILLION)
• TABLE 225. NORTH AMERICA ECHINOCANDIN B MARKET SIZE, BY INTERMEDIATE FOR DERIVATIVES, 2018-2032 (USD MILLION)
• TABLE 226. NORTH AMERICA ECHINOCANDIN B MARKET SIZE, BY FINISHED DOSAGE FORM, 2018-2032 (USD MILLION)
• TABLE 227. NORTH AMERICA ECHINOCANDIN B MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
• TABLE 228. NORTH AMERICA ECHINOCANDIN B MARKET SIZE, BY INTRAVENOUS, 2018-2032 (USD MILLION)
• TABLE 229. NORTH AMERICA ECHINOCANDIN B MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
• TABLE 230. NORTH AMERICA ECHINOCANDIN B MARKET SIZE, BY LYOPHILIZED POWDER, 2018-2032 (USD MILLION)
• TABLE 231. NORTH AMERICA ECHINOCANDIN B MARKET SIZE, BY DOSAGE REGIMEN, 2018-2032 (USD MILLION)
• TABLE 232. NORTH AMERICA ECHINOCANDIN B MARKET SIZE, BY ONCE DAILY, 2018-2032 (USD MILLION)
• TABLE 233. NORTH AMERICA ECHINOCANDIN B MARKET SIZE, BY TWICE DAILY, 2018-2032 (USD MILLION)
• TABLE 234. NORTH AMERICA ECHINOCANDIN B MARKET SIZE, BY PACKAGING, 2018-2032 (USD MILLION)
• TABLE 235. NORTH AMERICA ECHINOCANDIN B MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
• TABLE 236. NORTH AMERICA ECHINOCANDIN B MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2032 (USD MILLION)
• TABLE 237. NORTH AMERICA ECHINOCANDIN B MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
• TABLE 238. NORTH AMERICA ECHINOCANDIN B MARKET SIZE, BY THERAPEUTIC DEVELOPMENT, 2018-2032 (USD MILLION)
• TABLE 239. NORTH AMERICA ECHINOCANDIN B MARKET SIZE, BY COMMERCIAL PRODUCTION, 2018-2032 (USD MILLION)
• TABLE 240. NORTH AMERICA ECHINOCANDIN B MARKET SIZE, BY RESEARCH & DEVELOPMENT, 2018-2032 (USD MILLION)
• TABLE 241. NORTH AMERICA ECHINOCANDIN B MARKET SIZE, BY QUALITY CONTROL & ANALYTICS, 2018-2032 (USD MILLION)
• TABLE 242. NORTH AMERICA ECHINOCANDIN B MARKET SIZE, BY DIAGNOSTIC USE, 2018-2032 (USD MILLION)
• TABLE 243. NORTH AMERICA ECHINOCANDIN B MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
• TABLE 244. NORTH AMERICA ECHINOCANDIN B MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, 2018-2032 (USD MILLION)
• TABLE 245. LATIN AMERICA ECHINOCANDIN B MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 246. LATIN AMERICA ECHINOCANDIN B MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
• TABLE 247. LATIN AMERICA ECHINOCANDIN B MARKET SIZE, BY ACTIVE PHARMACEUTICAL INGREDIENT (API), 2018-2032 (USD MILLION)
• TABLE 248. LATIN AMERICA ECHINOCANDIN B MARKET SIZE, BY INTERMEDIATE FOR DERIVATIVES, 2018-2032 (USD MILLION)
• TABLE 249. LATIN AMERICA ECHINOCANDIN B MARKET SIZE, BY FINISHED DOSAGE FORM, 2018-2032 (USD MILLION)
• TABLE 250. LATIN AMERICA ECHINOCANDIN B MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
• TABLE 251. LATIN AMERICA ECHINOCANDIN B MARKET SIZE, BY INTRAVENOUS, 2018-2032 (USD MILLION)
• TABLE 252. LATIN AMERICA ECHINOCANDIN B MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
• TABLE 253. LATIN AMERICA ECHINOCANDIN B MARKET SIZE, BY LYOPHILIZED POWDER, 2018-2032 (USD MILLION)
• TABLE 254. LATIN AMERICA ECHINOCANDIN B MARKET SIZE, BY DOSAGE REGIMEN, 2018-2032 (USD MILLION)
• TABLE 255. LATIN AMERICA ECHINOCANDIN B MARKET SIZE, BY ONCE DAILY, 2018-2032 (USD MILLION)
• TABLE 256. LATIN AMERICA ECHINOCANDIN B MARKET SIZE, BY TWICE DAILY, 2018-2032 (USD MILLION)
• TABLE 257. LATIN AMERICA ECHINOCANDIN B MARKET SIZE, BY PACKAGING, 2018-2032 (USD MILLION)
• TABLE 258. LATIN AMERICA ECHINOCANDIN B MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
• TABLE 259. LATIN AMERICA ECHINOCANDIN B MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2032 (USD MILLION)
• TABLE 260. LATIN AMERICA ECHINOCANDIN B MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
• TABLE 261. LATIN AMERICA ECHINOCANDIN B MARKET SIZE, BY THERAPEUTIC DEVELOPMENT, 2018-2032 (USD MILLION)
• TABLE 262. LATIN AMERICA ECHINOCANDIN B MARKET SIZE, BY COMMERCIAL PRODUCTION, 2018-2032 (USD MILLION)
• TABLE 263. LATIN AMERICA ECHINOCANDIN B MARKET SIZE, BY RESEARCH & DEVELOPMENT, 2018-2032 (USD MILLION)
• TABLE 264. LATIN AMERICA ECHINOCANDIN B MARKET SIZE, BY QUALITY CONTROL & ANALYTICS, 2018-2032 (USD MILLION)
• TABLE 265. LATIN AMERICA ECHINOCANDIN B MARKET SIZE, BY DIAGNOSTIC USE, 2018-2032 (USD MILLION)
• TABLE 266. LATIN AMERICA ECHINOCANDIN B MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
• TABLE 267. LATIN AMERICA ECHINOCANDIN B MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, 2018-2032 (USD MILLION)
• TABLE 268. EUROPE, MIDDLE EAST & AFRICA ECHINOCANDIN B MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
• TABLE 269. EUROPE, MIDDLE EAST & AFRICA ECHINOCANDIN B MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
• TABLE 270. EUROPE, MIDDLE EAST & AFRICA ECHINOCANDIN B MARKET SIZE, BY ACTIVE PHARMACEUTICAL INGREDIENT (API), 2018-2032 (USD MILLION)
• TABLE 271. EUROPE, MIDDLE EAST & AFRICA ECHINOCANDIN B MARKET SIZE, BY INTERMEDIATE FOR DERIVATIVES, 2018-2032 (USD MILLION)
• TABLE 272. EUROPE, MIDDLE EAST & AFRICA ECHINOCANDIN B MARKET SIZE, BY FINISHED DOSAGE FORM, 2018-2032 (USD MILLION)
• TABLE 273. EUROPE, MIDDLE EAST & AFRICA ECHINOCANDIN B MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
• TABLE 274. EUROPE, MIDDLE EAST & AFRICA ECHINOCANDIN B MARKET SIZE, BY INTRAVENOUS, 2018-2032 (USD MILLION)
• TABLE 275. EUROPE, MIDDLE EAST & AFRICA ECHINOCANDIN B MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
• TABLE 276. EUROPE, MIDDLE EAST & AFRICA ECHINOCANDIN B MARKET SIZE, BY LYOPHILIZED POWDER, 2018-2032 (USD MILLION)
• TABLE 277. EUROPE, MIDDLE EAST & AFRICA ECHINOCANDIN B MARKET SIZE, BY DOSAGE REGIMEN, 2018-2032 (USD MILLION)
• TABLE 278. EUROPE, MIDDLE EAST & AFRICA ECHINOCANDIN B MARKET SIZE, BY ONCE DAILY, 2018-2032 (USD MILLION)
• TABLE 279. EUROPE, MIDDLE EAST & AFRICA ECHINOCANDIN B MARKET SIZE, BY TWICE DAILY, 2018-2032 (USD MILLION)
• TABLE 280. EUROPE, MIDDLE EAST & AFRICA ECHINOCANDIN B MARKET SIZE, BY PACKAGING, 2018-2032 (USD MILLION)
• TABLE 281. EUROPE, MIDDLE EAST & AFRICA ECHINOCANDIN B MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
• TABLE 282. EUROPE, MIDDLE EAST & AFRICA ECHINOCANDIN B MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2032 (USD MILLION)
• TABLE 283. EUROPE, MIDDLE EAST & AFRICA ECHINOCANDIN B MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
• TABLE 284. EUROPE, MIDDLE EAST & AFRICA ECHINOCANDIN B MARKET SIZE, BY THERAPEUTIC DEVELOPMENT, 2018-2032 (USD MILLION)
• TABLE 285. EUROPE, MIDDLE EAST & AFRICA ECHINOCANDIN B MARKET SIZE, BY COMMERCIAL PRODUCTION, 2018-2032 (USD MILLION)
• TABLE 286. EUROPE, MIDDLE EAST & AFRICA ECHINOCANDIN B MARKET SIZE, BY RESEARCH & DEVELOPMENT, 2018-2032 (USD MILLION)
• TABLE 287. EUROPE, MIDDLE EAST & AFRICA ECHINOCANDIN B MARKET SIZE, BY QUALITY CONTROL & ANALYTICS, 2018-2032 (USD MILLION)
• TABLE 288. EUROPE, MIDDLE EAST & AFRICA ECHINOCANDIN B MARKET SIZE, BY DIAGNOSTIC USE, 2018-2032 (USD MILLION)
• TABLE 289. EUROPE, MIDDLE EAST & AFRICA ECHINOCANDIN B MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
• TABLE 290. EUROPE, MIDDLE EAST & AFRICA ECHINOCANDIN B MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, 2018-2032 (USD MILLION)
• TABLE 291. EUROPE ECHINOCANDIN B MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 292. EUROPE ECHINOCANDIN B MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
• TABLE 293. EUROPE ECHINOCANDIN B MARKET SIZE, BY ACTIVE PHARMACEUTICAL INGREDIENT (API), 2018-2032 (USD MILLION)
• TABLE 294. EUROPE ECHINOCANDIN B MARKET SIZE, BY INTERMEDIATE FOR DERIVATIVES, 2018-2032 (USD MILLION)
• TABLE 295. EUROPE ECHINOCANDIN B MARKET SIZE, BY FINISHED DOSAGE FORM, 2018-2032 (USD MILLION)
• TABLE 296. EUROPE ECHINOCANDIN B MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
• TABLE 297. EUROPE ECHINOCANDIN B MARKET SIZE, BY INTRAVENOUS, 2018-2032 (USD MILLION)
• TABLE 298. EUROPE ECHINOCANDIN B MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
• TABLE 299. EUROPE ECHINOCANDIN B MARKET SIZE, BY LYOPHILIZED POWDER, 2018-2032 (USD MILLION)
• TABLE 300. EUROPE ECHINOCANDIN B MARKET SIZE, BY DOSAGE REGIMEN, 2018-2032 (USD MILLION)
• TABLE 301. EUROPE ECHINOCANDIN B MARKET SIZE, BY ONCE DAILY, 2018-2032 (USD MILLION)
• TABLE 302. EUROPE ECHINOCANDIN B MARKET SIZE, BY TWICE DAILY, 2018-2032 (USD MILLION)
• TABLE 303. EUROPE ECHINOCANDIN B MARKET SIZE, BY PACKAGING, 2018-2032 (USD MILLION)
• TABLE 304. EUROPE ECHINOCANDIN B MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
• TABLE 305. EUROPE ECHINOCANDIN B MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2032 (USD MILLION)
• TABLE 306. EUROPE ECHINOCANDIN B MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
• TABLE 307. EUROPE ECHINOCANDIN B MARKET SIZE, BY THERAPEUTIC DEVELOPMENT, 2018-2032 (USD MILLION)
• TABLE 308. EUROPE ECHINOCANDIN B MARKET SIZE, BY COMMERCIAL PRODUCTION, 2018-2032 (USD MILLION)
• TABLE 309. EUROPE ECHINOCANDIN B MARKET SIZE, BY RESEARCH & DEVELOPMENT, 2018-2032 (USD MILLION)
• TABLE 310. EUROPE ECHINOCANDIN B MARKET SIZE, BY QUALITY CONTROL & ANALYTICS, 2018-2032 (USD MILLION)
• TABLE 311. EUROPE ECHINOCANDIN B MARKET SIZE, BY DIAGNOSTIC USE, 2018-2032 (USD MILLION)
• TABLE 312. EUROPE ECHINOCANDIN B MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
• TABLE 313. EUROPE ECHINOCANDIN B MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, 2018-2032 (USD MILLION)
• TABLE 314. MIDDLE EAST ECHINOCANDIN B MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 315. MIDDLE EAST ECHINOCANDIN B MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
• TABLE 316. MIDDLE EAST ECHINOCANDIN B MARKET SIZE, BY ACTIVE PHARMACEUTICAL INGREDIENT (API), 2018-2032 (USD MILLION)
• TABLE 317. MIDDLE EAST ECHINOCANDIN B MARKET SIZE, BY INTERMEDIATE FOR DERIVATIVES, 2018-2032 (USD MILLIO